A new phase 1 safety trial has demonstrated that idarubicin-loaded beads are well tolerated by patients but are toxic to liver cancer cells. Idarubicin is an anthracycline that is currently used to treat leukemias.
Two months into the 21-patient trial, the tumors of 28% of patients had complete responses to the drug, and the tumors of 24% of patients had a partial response. The findings are published in Alimentary Pharmacology and Therapeutics.
###
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.